Updated:
Halozyme Therapeutics
Helen Torley has led Halozyme since 2014, building a royalty-backed biotech that licenses its ENHANZE drug-delivery technology to pharma giants.
Halozyme Therapeutics
Halozyme Therapeutics was founded in 1998 and has been led by CEO Helen Torley since 2014. The company is structured as a publicly traded biotechnology firm headquartered in San Diego, but its economic model is an outlier: it operates more like a royalty-backed specialty finance vehicle than a traditional drug developer. The core asset is ENHANZE, a recombinant human hyaluronidase enzyme that enables large-volume biologic drugs to be injected subcutaneously rather than intravenously. Halozyme out-licenses this technology to pharmaceutical partners including Roche, Johnson & Johnson, Pfizer, Bristol Myers Squibb, and argenx. Partners use ENHANZE to extend patent life, improve patient convenience, and differentiate branded biologics. The geographic footprint spans the United States, Europe, and Japan through these global licensing agreements. Halozyme earns royalty revenue on partnered product sales in the mid-single-digit percentage range. Key commercial products using ENHANZE include Roche's Tecentriq Hybreza, Johnson & Johnson's Darzalex Faspro, and argenx's Vyvgart Hytrulo. In 2022, Halozyme acquired Antares Pharma for approximately $960 million in cash, adding a specialty drug-delivery business with its own royalty-bearing commercial products. The transaction diversified revenue beyond ENHANZE royalties. Professional headcount was not publicly broken out as a stand-alone figure in recent filings, but the company operates from San Diego, with additional operations gained through the Antares acquisition in Minnesota. Philanthropic structures or family-office dynamics do not apply to this corporate entity. Halozyme's structural differentiator is a capital-light royalty model inside a public-company wrapper. Unlike most biotechs, it carries no clinical-stage pipeline risk and generates consistent free cash flow from partnered products. The governance reflects this hybrid nature: a public board, standard executive compensation, and a stated capital-allocation priority of returning cash to shareholders through share repurchases rather than internal R&D investment.
General information
Firm type
Asset Manager
Year founded
1998
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
Helen Torley
President and Chief Executive Officer
Sector focus
Frequently asked questions
Is Halozyme a biotech company or a royalty business?
Halozyme is a publicly traded biotechnology company whose economics resemble a specialty-finance royalty vehicle. It does not develop its own late-stage drug pipeline. Instead, it licenses its ENHANZE drug-delivery enzyme to pharmaceutical partners and earns mid-single-digit royalties on their product sales. The company's free cash flow generation and share-buyback program reinforce this capital-light, royalty-backed structure.
How does ENHANZE technology work?
ENHANZE uses recombinant human hyaluronidase to temporarily degrade hyaluronan in the subcutaneous space, allowing large-volume biologic drugs to be injected under the skin rather than intravenously. For pharmaceutical partners, this can extend patent protection, reduce clinic time, and improve patient adherence. Halozyme partners with drug developers who reformulate their existing biologics with ENHANZE, typically after mid-stage clinical trials.
Who are Halozyme's largest partners?
Halozyme's disclosed partners include Roche, Johnson & Johnson, Pfizer, Bristol Myers Squibb, argenx, and Takeda. Commercial products using ENHANZE include Darzalex Faspro for multiple myeloma, Tecentriq Hybreza for cancer, and Vyvgart Hytrulo for generalized myasthenia gravis. The revenue concentration risks are meaningful because a few blockbuster partnered products drive most royalty income.
What was the Antares Pharma acquisition about?
In 2022, Halozyme acquired Antares Pharma for roughly $960 million in cash. Antares brought a commercial specialty drug-delivery business with its own royalty-bearing products, including an auto-injector platform. The deal diversified Halozyme's revenue away from pure ENHANZE royalties and added an operating business in Minnesota.
How does Halozyme allocate capital?
Halozyme's stated capital-allocation priorities emphasize returning cash to shareholders through share repurchases, alongside targeted business-development deals. The company does not invest heavily in internal early-stage R&D, a posture that distinguishes it from most biotech firms. The board authorizes buyback programs funded by operating cash flow.
What happens when ENHANZE patents expire?
ENHANZE is protected by a portfolio of patents, but patent expiry timeline is a known risk factor in the royalty model. Halozyme manages this by locking in long-term licensing agreements with staggered expiration dates across its partner portfolio. The diversification across multiple partners, products, and therapeutic areas partially mitigates concentration risk, though individual patent cliffs can materially affect royalty revenue over time.
Is Halozyme structured as a family office or do insiders control the entity?
Halozyme is a publicly traded corporation with a widely held shareholder base; it is not a family office. CEO Helen Torley leads an executive team reporting to an independent board of directors. No individual or family branch controls a majority voting stake according to public filings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: